Salix Pharmaceuticals Ltd (SLXP) Reports Q4 EPS of $0.56, Sales Top Expectations

Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q4 EPS of $0.56, which may not compare to the analyst estimate of $0.96. Revenue for the quarter came in at $155.2 million versus the consensus estimate of $152.62 million.

For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
• Business First Bancshares, Inc. (BFST) Misses Q1 EPS by 7c
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance